Improvement in lung cancer outcomes with targeted therapies: an update for family physicians

Area of Science:

• Oncology
• Pharmacology

Background:

• Targeted therapy represents a paradigm shift in lung cancer treatment over the past decade.
• Tailored drugs offer superior efficacy and reduced toxicity compared to traditional cytotoxic agents for molecularly selected patients.

Purpose of the Study:

• To provide an updated overview of non-small-cell lung cancer (NSCLC) treatment, focusing on targeted therapies.
• To integrate molecular profile assessment with evidence on tyrosine kinase inhibitor (TKI) efficacy and toxicity.
• To promote enhanced collaboration between specialists and family physicians in cancer care.

Main Methods:

• Review of current literature on targeted agents for NSCLC.
• Integration of molecular profiling, efficacy data, and toxicity profiles of approved TKIs.
• Analysis of the role of family physicians in managing NSCLC patients on targeted therapy.

Main Results:

• Epidermal growth factor receptor (EGFR) TKIs (erlotinib, gefitinib) and anaplastic lymphoma kinase (ALK) inhibitor (crizotinib) are approved targeted agents for NSCLC.
• Targeted therapies provide significant benefits and improved quality of life in molecularly selected NSCLC patients.
• Family physicians are crucial for managing toxicities and providing patient support.

Conclusions:

• Targeted therapies have fundamentally altered NSCLC treatment paradigms.
• Molecular profiling is essential for identifying patients who benefit from specific TKIs.
• Close collaboration between oncologists and family physicians is vital for optimal NSCLC patient management.